S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
How major US stock indexes fared Friday, 2/23/2024
Closing prices for crude oil, gold and other commodities
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Warren Buffett tells investors to ignore Wall Street pundits while paying tribute to Charlie Munger
MarketBeat Week in Review – 2/19 - 2/23
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
How major US stock indexes fared Friday, 2/23/2024
Closing prices for crude oil, gold and other commodities
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Warren Buffett tells investors to ignore Wall Street pundits while paying tribute to Charlie Munger
MarketBeat Week in Review – 2/19 - 2/23
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
How major US stock indexes fared Friday, 2/23/2024
Closing prices for crude oil, gold and other commodities
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Warren Buffett tells investors to ignore Wall Street pundits while paying tribute to Charlie Munger
MarketBeat Week in Review – 2/19 - 2/23
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
How major US stock indexes fared Friday, 2/23/2024
Closing prices for crude oil, gold and other commodities
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Warren Buffett tells investors to ignore Wall Street pundits while paying tribute to Charlie Munger
MarketBeat Week in Review – 2/19 - 2/23

JATT Acquisition (JATT) Competitors

$3.65
-0.01 (-0.27%)
(As of 02/23/2024 ET)

JATT vs. CGTX, CDTX, IKNA, CRIS, PASG, LGST, AVRO, QNCX, CASI, and CRDF

Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Cognition Therapeutics (CGTX), Cidara Therapeutics (CDTX), Ikena Oncology (IKNA), Curis (CRIS), Passage Bio (PASG), Semper Paratus Acquisition (LGST), AVROBIO (AVRO), Quince Therapeutics (QNCX), CASI Pharmaceuticals (CASI), and Cardiff Oncology (CRDF). These companies are all part of the "biological products, except diagnostic" industry.

JATT Acquisition vs.

Cognition Therapeutics (NASDAQ:CGTX) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Cognition Therapeutics' return on equity of -49.58% beat JATT Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Cognition TherapeuticsN/A -65.53% -51.07%
JATT Acquisition N/A -49.58%2.84%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cognition TherapeuticsN/AN/A-$21.40M-$0.79-2.53
JATT AcquisitionN/AN/A$6.85MN/AN/A

Cognition Therapeutics received 6 more outperform votes than JATT Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
Cognition TherapeuticsOutperform Votes
6
46.15%
Underperform Votes
7
53.85%
JATT AcquisitionN/AN/A

In the previous week, Cognition Therapeutics had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Cognition Therapeutics and 0 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 0.00 equaled Cognition Therapeutics'average media sentiment score.

Company Overall Sentiment
Cognition Therapeutics Neutral
JATT Acquisition Neutral

23.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 23.8% of Cognition Therapeutics shares are owned by insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cognition Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 200.00%. Given JATT Acquisition's higher possible upside, equities research analysts plainly believe Cognition Therapeutics is more favorable than JATT Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cognition Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
JATT Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Cognition Therapeutics beats JATT Acquisition on 5 of the 9 factors compared between the two stocks.


Get JATT Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JATT vs. The Competition

MetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$62.96M$2.76B$5.11B$17.44B
Dividend YieldN/A2.36%2.86%3.57%
P/E RatioN/A4.13161.7120.81
Price / SalesN/A308.373,052.277.27
Price / Cash27.0827.9798.6217.54
Price / Book-6.894.054.396.09
Net Income$6.85M$59.66M$113.02M$870.05M
7 Day Performance-6.41%-0.16%0.93%-0.34%
1 Month Performance-14.12%10.44%7.30%2.49%
1 Year PerformanceN/A8.83%10.68%89.29%

JATT Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CGTX
Cognition Therapeutics
2.3269 of 5 stars
$2.00
+2.0%
$6.00
+200.0%
+19.8%$64.24MN/A-2.5322News Coverage
Positive News
Gap Up
CDTX
Cidara Therapeutics
3.5198 of 5 stars
$0.71
-1.4%
$4.67
+558.2%
-58.1%$64.12M$64.29M-1.8273
IKNA
Ikena Oncology
2.874 of 5 stars
$1.39
+1.5%
$10.67
+667.4%
-64.2%$67.08M$15.62M-0.8657High Trading Volume
CRIS
Curis
1.8964 of 5 stars
$10.14
-3.3%
$37.33
+268.2%
-24.5%$59.77M$10.02M-1.1349News Coverage
PASG
Passage Bio
3.269 of 5 stars
$1.30
+0.8%
$7.00
+438.5%
+7.1%$71.27MN/A-0.6385Gap Down
LGST
Semper Paratus Acquisition
0 of 5 stars
$4.51
flat
N/A-58.7%$71.35MN/A0.002,021Positive News
Gap Up
AVRO
AVROBIO
1.6412 of 5 stars
$1.30
+0.8%
$3.33
+156.4%
-2.3%$57.94MN/A-13.0078Gap Down
High Trading Volume
QNCX
Quince Therapeutics
0.6154 of 5 stars
$1.35
+5.5%
N/A+33.0%$57.87MN/A0.0021Upcoming Earnings
News Coverage
CASI
CASI Pharmaceuticals
3.9521 of 5 stars
$5.60
-3.4%
$12.00
+114.3%
+189.1%$74.60M$42.26M-1.86224
CRDF
Cardiff Oncology
1.804 of 5 stars
$1.70
-1.7%
$13.00
+664.7%
-5.6%$75.96M$390,000.00-1.8525Upcoming Earnings
News Coverage

Related Companies and Tools

This page (NYSE:JATT) was last updated on 2/24/2024 by MarketBeat.com Staff